Pirenne J, Van Gelder F, Coosemans W, Aerts R, Gunson B, Koshiba T, Fourneau I, Mirza D, Van Steenbergen W, Fevery J, Nevens F, McMaster P
Liver Transplant Group, Catholic University of Leuven, Leuven, Belgium.
Liver Transpl. 2001 Jun;7(6):540-5. doi: 10.1053/jlts.2001.24641.
The development of biliary strictures (BSs) after liver transplantation (LT) continues to affect 10% to 30% of patients, causing substantial morbidity. The cause of BSs is multifactorial, including technical, immune, and, in particular, ischemic factors. The importance of adequate flushing of the peribiliary arterial tree has been stressed. We hypothesized that high-viscosity (HV) preservation solutions in the donor do not completely flush the small donor peribiliary plexus, leading to inadequate preservation of the bile ducts and posttransplant BSs. To test this hypothesis, we retrospectively compared the incidence of BSs in 2 groups of adults undergoing LT using different types of aortic preservation solution in the donor: group 1 (n = 24), low-viscosity (LV) Marshall solution; and group 2 (n = 27), HV University of Wisconsin (UW) solution. All donors in both groups received additional portal flushes with UW. All LTs were performed between November 1995 and August 1998 at 2 centers by the same surgeon, eliminating a technical bias. Terminal duct-to-duct anastomosis was performed in all recipients except 1 patient in group 1, who underwent a bile duct-to-jejunum anastomosis. BSs were first suspected on clinical and biochemical grounds and then confirmed by endoscopic retrograde cholangiopancreatography. Identical medical protocols were used in all patients. One-year patient survival rates in groups 1 and 2 were 92% and 100%, respectively (P =.9). One-year graft survival was identical to patient survival. The incidence of BSs in group 1 was 4.1% (1 of 24 patients), compared to 29.7% in group 2 (8 of 27 patients; P =.02). The BS in group 1 occurred 4 months post-LT and was anastomotic. BSs in group 2 occurred between 1 and 12 months post-LT and were anastomotic, extrahepatic, intrahepatic, or combined intrahepatic and extrahepatic. There were no significant differences in the following factors between groups 1 and 2: donor age, local versus imported liver, split-liver or full-liver transplantation, incidence of multiple vessels in the donor liver, indications for LT, recipient age, T-tube versus no T-tube, post-LT peak aspartate aminotransferase level, and treatment for rejection. There was no hepatic artery thrombosis or primary nonfunction in either group. Interestingly, cold ischemia time (CIT) was longer in group 1, which had the least incidence of BSs (692 +/- 190 v 535 +/- 129 minutes in group 2; P =.001). Follow-up was longer in group 1 (28.9 +/- 8.3 v 15.6 +/- 8 months in group 2; P =.0001). Preservation costs per procurement were 1.9 times greater in the UW group than in the Marshall group. Donor aortic flushing with an HV preservation solution leads to more frequent BSs compared with an LV preservation solution. The impact of preservation solution outweighs the previously described deleterious impact of prolonged CIT. Mixed preservation solution (Marshall solution in the aorta, UW solution in the portal vein) might protect against BS formation while providing optimal liver graft preservation, function, and survival despite a mean CIT longer than 10 hours.
肝移植(LT)后胆管狭窄(BSs)的发生仍影响着10%至30%的患者,导致严重的发病情况。BSs的病因是多因素的,包括技术、免疫因素,尤其是缺血因素。充分冲洗肝门周围动脉树的重要性已得到强调。我们推测供体中高粘度(HV)保存液不能完全冲洗供体小肝门周围神经丛,导致胆管保存不充分及移植后BSs。为验证这一假设,我们回顾性比较了两组接受LT的成年患者中BSs的发生率,这两组患者在供体中使用了不同类型的主动脉保存液:第1组(n = 24),低粘度(LV)马歇尔溶液;第2组(n = 27),HV威斯康星大学(UW)溶液。两组所有供体均额外用UW进行门静脉冲洗。所有LT均于1995年11月至1998年8月在2个中心由同一位外科医生进行,消除了技术偏差。除第1组1例患者行胆管空肠吻合术外,所有受者均行端端胆管吻合术。BSs首先根据临床和生化依据怀疑,然后通过内镜逆行胰胆管造影术确诊。所有患者均采用相同的医疗方案。第1组和第2组患者1年生存率分别为92%和100%(P = 0.9)。1年移植物生存率与患者生存率相同。第1组BSs发生率为4.1%(24例患者中的1例),而第2组为29.7%(27例患者中的8例;P = 0.02)。第1组的BS发生在LT后4个月,为吻合口处狭窄。第2组的BSs发生在LT后1至12个月,为吻合口处、肝外、肝内或肝内外联合狭窄。第1组和第2组在以下因素方面无显著差异:供体年龄、本地肝与进口肝、劈离式肝移植或全肝移植、供体肝多支血管发生率、LT指征、受者年龄、有无T管、LT后谷草转氨酶峰值水平以及抗排斥治疗。两组均无肝动脉血栓形成或原发性无功能。有趣的是,BSs发生率最低的第1组冷缺血时间(CIT)更长(第1组为692±190分钟,第2组为535±129分钟;P = 0.001)。第1组随访时间更长(第1组为28.9±8.3个月,第2组为15.6±8个月;P = 0.0001)。每次获取的保存成本UW组比马歇尔组高1.9倍。与LV保存液相比,用HV保存液冲洗供体主动脉导致BSs更频繁。保存液的影响超过了先前描述的CIT延长的有害影响。混合保存液(主动脉用马歇尔溶液,门静脉用UW溶液)可能预防BSs形成,同时尽管平均CIT超过10小时,但能提供最佳的肝移植物保存、功能和生存。